Literature DB >> 31829048

An update on clinical, pathological, diagnostic, and therapeutic perspectives of childhood leukodystrophies.

Mahmoud Reza Ashrafi1, Man Amanat2, Masoud Garshasbi3, Reyhaneh Kameli1, Yalda Nilipour4, Morteza Heidari1, Zahra Rezaei1, Ali Reza Tavasoli1.   

Abstract

Introduction: Leukodystrophies constitute heterogenous group of rare heritable disorders primarily affecting the white matter of central nervous system. These conditions are often under-appreciated among physicians. The first clinical manifestations of leukodystrophies are often nonspecific and can occur in different ages from neonatal to late adulthood periods. The diagnosis is, therefore, challenging in most cases.Area covered: Herein, the authors discuss different aspects of leukodystrophies. The authors used MEDLINE, EMBASE, and GOOGLE SCHOLAR to provide an extensive update about epidemiology, classifications, pathology, clinical findings, diagnostic tools, and treatments of leukodystrophies. Comprehensive evaluation of clinical findings, brain magnetic resonance imaging, and genetic studies play the key roles in the early diagnosis of individuals with leukodystrophies. No cure is available for most heritable white matter disorders but symptomatic treatments can significantly decrease the burden of events. New genetic methods and stem cell transplantation are also under investigation to further increase the quality and duration of life in affected population.Expert opinion: The improvements in molecular diagnostic tools allow us to identify the meticulous underlying etiology of leukodystrophies and result in higher diagnostic rates, new classifications of leukodystrophies based on genetic information, and replacement of symptomatic managements with more specific targeted therapies.Abbreviations: 4H: Hypomyelination, hypogonadotropic hypogonadism and hypodontia; AAV: Adeno-associated virus; AD: autosomal dominant; AGS: Aicardi-Goutieres syndrome; ALSP: Axonal spheroids and pigmented glia; APGBD: Adult polyglucosan body disease; AR: autosomal recessive; ASO: Antisense oligonucleotide therapy; AxD: Alexander disease; BAEP: Brainstem auditory evoked potentials; CAA: Cerebral amyloid angiopathy; CADASIL: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; CARASAL: Cathepsin A-related arteriopathy with strokes and leukoencephalopathy; CARASIL: Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy; CGH: Comparative genomic hybridization; ClC2: Chloride Ion Channel 2; CMTX: Charcot-Marie-Tooth disease, X-linked; CMV: Cytomegalovirus; CNS: central nervous system; CRISP/Cas9: Clustered regularly interspaced short palindromic repeat/CRISPR-associated 9; gRNA: Guide RNA; CTX: Cerebrotendinous xanthomatosis; DNA: Deoxyribonucleic acid; DSB: Double strand breaks; DTI: Diffusion tensor imaging; FLAIR: Fluid attenuated inversion recovery; GAN: Giant axonal neuropathy; H-ABC: Hypomyelination with atrophy of basal ganglia and cerebellum; HBSL: Hypomyelination with brainstem and spinal cord involvement and leg spasticity; HCC: Hypomyelination with congenital cataracts; HEMS: Hypomyelination of early myelinated structures; HMG CoA: Hydroxy methylglutaryl CoA; HSCT: Hematopoietic stem cell transplant; iPSC: Induced pluripotent stem cells; KSS: Kearns-Sayre syndrome; L-2-HGA: L-2-hydroxy glutaric aciduria; LBSL: Leukoencephalopathy with brainstem and spinal cord involvement and elevated lactate; LCC: Leukoencephalopathy with calcifications and cysts; LTBL: Leukoencephalopathy with thalamus and brainstem involvement and high lactate; MELAS: Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke; MERRF: Myoclonic epilepsy with ragged red fibers; MLC: Megalencephalic leukoencephalopathy with subcortical cysts; MLD: metachromatic leukodystrophy; MRI: magnetic resonance imaging; NCL: Neuronal ceroid lipofuscinosis; NGS: Next generation sequencing; ODDD: Oculodentodigital dysplasia; PCWH: Peripheral demyelinating neuropathy-central-dysmyelinating leukodystrophy-Waardenburg syndrome-Hirschprung disease; PMD: Pelizaeus-Merzbacher disease; PMDL: Pelizaeus-Merzbacher-like disease; RNA: Ribonucleic acid; TW: T-weighted; VWM: Vanishing white matter; WES: whole exome sequencing; WGS: whole genome sequencing; X-ALD: X-linked adrenoleukodystrophy; XLD: X-linked dominant; XLR: X-linked recessive.

Entities:  

Keywords:  White matter disorder; adolescents; children; diagnosis; incidence; leukodystrophy; treatment

Mesh:

Year:  2019        PMID: 31829048     DOI: 10.1080/14737175.2020.1699060

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  13 in total

1.  Rare Diseases in Glycosphingolipid Metabolism.

Authors:  Hongwen Zhou; Zhoulu Wu; Yiwen Wang; Qinyi Wu; Moran Hu; Shuai Ma; Min Zhou; Yan Sun; Baowen Yu; Jingya Ye; Wanzi Jiang; Zhenzhen Fu; Yingyun Gong
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 2.  [Research advances in the clinical genetics of leukodystrophy in children].

Authors:  Zhe-Lan Huang; Wen-Hao Zhou
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-06-15

3.  Symptomatic care of late-onset Alexander disease presenting with area postrema-like syndrome with prednisolone; a case report.

Authors:  Safoura Zardadi; Ehsan Razmara; Maryam Rasoulinezhad; Meisam Babaei; Mohammad Reza Ashrafi; Neda Pak; Masoud Garshasbi; Ali Reza Tavasoli
Journal:  BMC Pediatr       Date:  2022-07-13       Impact factor: 2.567

Review 4.  Canavan Disease as a Model for Gene Therapy-Mediated Myelin Repair.

Authors:  Anoushka Lotun; Dominic J Gessler; Guangping Gao
Journal:  Front Cell Neurosci       Date:  2021-04-23       Impact factor: 6.147

5.  Histone Acetylation Defects in Brain Precursor Cells: A Potential Pathogenic Mechanism Causing Proliferation and Differentiation Dysfunctions in Mitochondrial Aspartate-Glutamate Carrier Isoform 1 Deficiency.

Authors:  Eleonora Poeta; Sabrina Petralla; Giorgia Babini; Brunaldo Renzi; Luigi Celauro; Maria Chiara Magnifico; Simona Nicole Barile; Martina Masotti; Francesca De Chirico; Francesca Massenzio; Luigi Viggiano; Luigi Palmieri; Marco Virgili; Francesco Massimo Lasorsa; Barbara Monti
Journal:  Front Cell Neurosci       Date:  2022-01-12       Impact factor: 5.505

6.  Case Report: Mutation in AIMP2/P38, the Scaffold for the Multi-Trna Synthetase Complex, and Association With Progressive Neurodevelopmental Disorders.

Authors:  Mahta Mazaheri; Mahdie Yavari; Hadi Zare Marzouni; Angela Stufano; Piero Lovreglio; Simona S'Amore; Hamid Reza Jahantigh
Journal:  Front Genet       Date:  2022-01-24       Impact factor: 4.599

Review 7.  Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases.

Authors:  Marianna Mekhaeil; Kumlesh Kumar Dev; Melissa Jane Conroy
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

Review 8.  Paroxysmal Movement Disorders.

Authors:  Susan Harvey; Mary D King; Kathleen M Gorman
Journal:  Front Neurol       Date:  2021-06-11       Impact factor: 4.003

Review 9.  Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches.

Authors:  Alisa A Shaimardanova; Daria S Chulpanova; Valeriya V Solovyeva; Aysilu I Mullagulova; Kristina V Kitaeva; Cinzia Allegrucci; Albert A Rizvanov
Journal:  Front Med (Lausanne)       Date:  2020-10-20

10.  Regional Difference in Myelination in Monocarboxylate Transporter 8 Deficiency: Case Reports and Literature Review of Cases in Japan.

Authors:  Hideyuki Iwayama; Tatsushi Tanaka; Kohei Aoyama; Masaharu Moroto; Shinsuke Adachi; Yasuko Fujisawa; Hiroki Matsuura; Kyoko Takano; Haruo Mizuno; Akihisa Okumura
Journal:  Front Neurol       Date:  2021-07-15       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.